Data as of Aug 29
| +0.08 / +1.18%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 14.00. The median estimate represents a +132.56% increase from the last price of 6.88.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.